Form 4: Allogene Therapeutics Director Arie Belldegrun Acquires Additional Shares in Registered Direct Offering

Director Arie Belldegrun reports acquisition of Allogene Therapeutics shares through direct purchase and entities he is associated with.

Summary

• On May 16, 2024, Arie Belldegrun, a director of Allogene Therapeutics, Inc., acquired shares of common stock through a registered direct offering.
• Belldegrun directly purchased 344,828 shares at $2.9 per share.
• Vida Ventures III, L.P. and Vida Ventures III A, L.P., entities associated with Belldegrun, acquired 1,724,137 shares at $2.9 per share.
• Following these transactions, Belldegrun's total beneficial ownership includes shares held directly, through Bellco Legacy LLC, Vida Ventures III, L.P. and Vida Ventures III-A, L.P., Bellco Legacy Trust, and Vida Ventures LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of share purchases by a director. The purchase itself could be seen as slightly positive, indicating confidence, but the filing is simply a required disclosure.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Directors and major shareholders often purchase shares in direct offerings, which can be seen as a sign of confidence in the company's future.

Stakeholder Impact

• The increased holdings of a director could be viewed positively by shareholders.

Key Dates